Publication | Closed Access

751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results

Viral HepatitisImmunologyAntiviral Drug DevelopmentHepatitisVirologyAntiviral TherapyPegylated Interferon Alpha-2bInfection ControlAntiviral DrugMedicinePhase 3Therapy-naïve Patients